Israeli oral drug delivery specialist Oramed Pharmaceuticals (TASE: ORMP) has provided an update regarding its ongoing clinical work.
Of most interest for investors will be the firm’s lead candidate, an oral formulation of insulin which, if successful, has the potential to shake up the market considerably.
The firm has now completed enrollment for a 90-day dose-ranging Phase IIb study of its oral insulin capsule, ORMD-0801, for type 2 diabetes. 80% of participants have now completed the trial, and the first results are expected by the end of the year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze